Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · ADMA Biologics (ADMA)

ADMA Biologics names Brad Tade chief financial officer and treasurer effective July 24, 2024

Neutral Impact 4 of 5 leadership Written later

ADMA Biologics promoted Brad Tade, its former vice president of financial operations, to chief financial officer and treasurer effective July 24, 2024. The company entered into an employment agreement with Mr. Tade, which sets a $435,000 base salary, a target bonus of 45% of salary, and equity grants of options and restricted stock units.

Key points

  • Brad Tade, age 51, joined ADMA in June 2023 as vice president, financial operations, and is now CFO and treasurer effective July 24, 2024
  • Base salary of $435,000 with a target annual cash bonus of 45% of base salary
  • Equity grant of an option to purchase 115,100 shares and 72,400 restricted stock units, vesting over four years

The filing

CompanyADMA Biologics (ADMA)
Form8-K, current report
Filed with the SECJul 26, 2024, 5:15 PM ET
Accession number0001140361-24-034440

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:49 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 26, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.